Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
Topics Covered
- Translational medicine
- Biomarker development
- Risk assessment
- Risk estimator
- Scoring system
- Structured approach
- Clinical pharmacology
- Interdisciplinary cooperation
Biography
Martin Wehling, MD, is full professor of clinical pharmacology at the University of Heidelberg. He is also board certified internist (cardiologist) and has longstanding experiences in basic science (cell physiology, steroid pharmacology, nongenomic steroid actions), clinical trials (translating basic science into human studies) and clinical medicine (invasive cardiology, endocrinology). In 2004, he was appointed by AstraZeneca as director of discovery (=translational) medicine. In 2007, he returned to his academic position to further translational medicine by aligning academic and private activities to support biomedical innovation. His main tools are connecting distant players in the translational process, developing technological platforms and integrating them into the translational process, assembling, developing and profiling of biomarkers with particular assessment of their predictive value and developing smart translational plans to promote translatable projects.
Talk Citation
Wehling, M. (2022, September 12). Translational medicine: the risk of failure in delay and how to reduce it [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 7, 2024, from https://doi.org/10.69645/RQHJ5960.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Martin Wehling has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.